medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2021-34-35-38medalphabet-2344Research ArticleДЕРМАТОЛОГИЯDERMATOLOGYВоспалительные заболевания кишечника и устекинумаб у больных среднетяжелыми и тяжелыми формами псориазаDiseases of cardiovascular system in patients with moderate-to-severe and severe forms of psoriasishttps://orcid.org/0000-0002-8688-4876ХоткоА. А.HotkoA. A.

Хотко Алкес Асланчериевич, к. м. н., доцент, зам. гл. врача по медицинской части

Краснодар

Hotko Alkes A., PhD Med, associate professor, deputy chief physician

Krasnodar

alkes@inbox.ruhttps://orcid.org/0000-0003-0122-5319ПомазановаМ. Ю.PomazanovaM. Yu.

Помазанова Марина Юрьевна, зав. женским стационарным отделением

Краснодар

Pomazanova Marina Yu., head of Women’s Inpatient Dept

Krasnodar

mmm-marusya-mmm@mail.ruhttps://orcid.org/0000-0002-4543-9186ДурлештерМ. В.DurleshterM. V.

Дурлештер Марина Владимировна, врач ультразвуковой диагностики

Краснодар

Durleshter Marina V., ultrasound diagnostician

Krasnodar

durleshter88@mail.ruГБУЗ «Клинический кожно-венерологический диспансер» Минздрава Краснодарского краяРоссияClinical Dermatovenerologic DispensaryRussian FederationГБУЗ «Краевая клиническая больница № 2» Минздрава Краснодарского краяРоссияRegional Clinical Hospital No. 2Russian Federation202117122021034Дерматология (3)3538Copyright © Хотко А.А., Помазанова М.Ю., Дурлештер М.В., 20212021Хотко А.А., Помазанова М.Ю., Дурлештер М.В.Hotko A.A., Pomazanova M.Y., Durleshter M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2344

Псориаз относится к наиболее распространенным хроническим иммуноопосредованным заболеваниям кожи. Одна из широко обсуждаемых гастроэнтерологических коморбидностей псориаза – хронические воспалительные заболевания желудочно-кишечного тракта. В статье представлены результаты анализа историй болезни ГБУЗ «Клинический кожно-венерологический диспансер» Минздрава Краснодарского края (г. Краснодар) пациентов со среднетяжелой и тяжелой формами псориаза и сопутствующей патологией – воспалительными заболеваниями кишечника. Был проведен анализ 24 историй болезни пациентов со среднетяжелым и тяжелым течением псориаза, где можно увидеть клиническую и практическую значимость сочетанной патологии – псориаза и воспалительных заболеваний кишечника. Из анализа можно сделать вывод о прямой взаимосвязи между тяжестью течения кожного патологического процесса и развитием заболеваний кишечника, а также влияние устекинумаба на течение сочетанной патологии – псориаза, язвенного колита и болезни Крона.

Psoriasis is one of the most common chronic immune-mediated skin diseases. One of the widely discussed gastroenterological comorbidities of psoriasis is chronic inflammatory diseases of the gastrointestinal tract. The article presents the results of the analysis of the case histories of patients with moderate-to-severe and severe forms of psoriasis and concomitant pathology – inflammatory bowel diseases (Clinical Dermatovenerologic Dispensary, Krasnodar, Russia). The analysis of 16 case histories of patients with moderate-to-severe and severe psoriasis has been carried out, where one can see the clinical and practical significance of the combined pathology – psoriasis and inflammatory bowel diseases. From the analysis, one can conclude that there is a direct relationship between the severity of the course of the skin pathological process and the development of intestinal diseases, as well as the influence of ustekinumab on the course of combined pathology – psoriasis, ulcerative colitis and Crohn’s disease.

псориазболезнь Кронаязвенный колитустекинумабpsoriasisCrohn’s diseaseulcerative colitisustekinumabReferencesAaron E. Walfish, MD, Mount Sinai Medical Center; Rafael Antonio Ching Companioni, MD, Digestive Diseases Center.Aaron E. Walfish, MD, Mount Sinai Medical Center; Rafael Antonio Ching Companioni, MD, Digestive Diseases Center.Шапина М. В., Нанаева Б. А., Варданян А. В. Эффективность и безопасность устекинумаба при болезни Крона (обзор литературы). Колопроктология. 2019; т. 18, № 3 (69), с. 119–130. Shapina M. V., Nanaeva B. A., Vardanyan A. V. Efficacy and safety of ustekinumab in Crohn’s disease (literature review). Coloproctology. 2019; Vol. 18, No. 3 (69), pp. 119–130.Shapina M. V., Nanaeva B. A., Vardanyan A. V. Efficacy and safety of ustekinumab in Crohn’s disease (literature review). Coloproctology. 2019; Vol. 18, No. 3 (69), pp. 119–130.Elder J. T., Bruce A. T., Gudjonsson J. E. et al. Molecular dissection of psoriasis: integrating genetics and biology. J. Invest. Dermatol. 2010. Vol. 130. No. 5. P. 1213–1226.Elder J. T., Bruce A. T., Gudjonsson J. E. et al. Molecular dissection of psoriasis: integrating genetics and biology. J. Invest. Dermatol. 2010. Vol. 130. No. 5. P. 1213–1226.Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 2010; 129 (3): 311–21. DOI: 10.1111/j.1365–2567.2009.03240.x.Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 2010; 129 (3): 311–21. DOI: 10.1111/j.1365–2567.2009.03240.x.Macaluso F. S., Orlando A., Cottone M. Anti-interleukin-12 and antiinterleukin-23 agents in Crohn’s disease. Exp Opin Biol Ther. 2019; 19 (2): 89–98. DOI: 10.1080/14712598.2019.1561850.Macaluso F. S., Orlando A., Cottone M. Anti-interleukin-12 and antiinterleukin-23 agents in Crohn’s disease. Exp Opin Biol Ther. 2019; 19 (2): 89–98. DOI: 10.1080/14712598.2019.1561850.Feagan B. G., Sandborn W. J., Gasink C., Jacobstein D., Lang Y., Friedman J. R. et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016; 375 (20): 1946–1960. DOI: 10.1056/NEJMoa1602773.Feagan B. G., Sandborn W. J., Gasink C., Jacobstein D., Lang Y., Friedman J. R. et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016; 375 (20): 1946–1960. DOI: 10.1056/NEJMoa1602773.Hanauer S. B., Sandborn W. J., Feagan B. G., Gasink C., Jacobstein D., Zou B. et al. IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn’s Disease. J Crohns Colitis. 2020; 14 (1): 23–32. DOI: 10.1093/ecco-jcc/jjz110.Hanauer S. B., Sandborn W. J., Feagan B. G., Gasink C., Jacobstein D., Zou B. et al. IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn’s Disease. J Crohns Colitis. 2020; 14 (1): 23–32. DOI: 10.1093/ecco-jcc/jjz110.McInnes I.B., Kavanaugh A., Gottlieb A. B., Puig L., Rahman P., Ritchlin C. et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1-year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013; 382 (9894): 780–789. DOI: 10.1016/S0140–6736(13)60594–2.McInnes I.B., Kavanaugh A., Gottlieb A. B., Puig L., Rahman P., Ritchlin C. et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1-year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013; 382 (9894): 780–789. DOI: 10.1016/S0140–6736(13)60594–2.Ritchlin C., Rahman P., Kavanaugh A., McInnes I.B., Puig L., Li S. et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014; 73 (6): 990–999. DOI: 10.1136/annrheumdis-2013–204655.Ritchlin C., Rahman P., Kavanaugh A., McInnes I.B., Puig L., Li S. et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014; 73 (6): 990–999. DOI: 10.1136/annrheumdis-2013–204655.Kavanaugh A, Ritchlin C, Rahman P, Puig L, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: Results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT‑2 trials. Ann Rheum Dis. 2014; 73: 1000–1006.Kavanaugh A, Ritchlin C, Rahman P, Puig L, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: Results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT‑2 trials. Ann Rheum Dis. 2014; 73: 1000–1006.Toichi E, Torres G, McCormick TS, Chang T, et al. An anti-IL12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol. 2006; 177: 4917–4926.Toichi E, Torres G, McCormick TS, Chang T, et al. An anti-IL12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol. 2006; 177: 4917–4926.Peluso I, Pallone F, Monteleone G. Interleukin-12 and Th1 immune response in Crohn’s disease: Pathogenetic relevance and therapeutic implication. World J Gastroenterol. 2006; 12: 5606–5610.Peluso I, Pallone F, Monteleone G. Interleukin-12 and Th1 immune response in Crohn’s disease: Pathogenetic relevance and therapeutic implication. World J Gastroenterol. 2006; 12: 5606–5610.Siakavellas SI, Bamias G. Role of the IL-23/IL-17 axis in Crohn’s disease. Discov Med. 2012; 14: 253–262. 28. Cote-Daigneault J, Bouin M, Lahaie R, Colombel JF, Poitras P.Siakavellas SI, Bamias G. Role of the IL-23/IL-17 axis in Crohn’s disease. Discov Med. 2012; 14: 253–262. 28. Cote-Daigneault J, Bouin M, Lahaie R, Colombel JF, Poitras P.Круглова Л. С., Львов А. Н., Каграманова А. В., Князев О. В. Псориаз и воспалительные заболевания кишечника: пути патогенеза и вопросы выбора генно-инженерных препаратов (обзор литературы). Альманах клинической медицины. 2019. № 6. Kruglova L. S., Lvov A. N., Kagramanova A. V., Knyazev O. V. Psoriasis and inflammatory bowel diseases: pathogenesis pathways and questions of the choice of genetically engineered drugs (literature review). Almanac of Clinical Medicine. 2019. No. 6.Kruglova L. S., Lvov A. N., Kagramanova A. V., Knyazev O. V. Psoriasis and inflammatory bowel diseases: pathogenesis pathways and questions of the choice of genetically engineered drugs (literature review). Almanac of Clinical Medicine. 2019. No. 6.

The authors declare that there are no conflicts of interest present.